Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2022-07-06 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorized and issued share capital, share options, convertibles, and other share-related arrangements for Pharmaron Beijing Co., Ltd. It includes data on share capital balances, increases/decreases, and adjustments to convertible bond conversion prices. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with Exchange Listing Rules. It is not an annual or interim financial report, nor an earnings release or management discussion. It is not a proxy, AGM material, or voting results announcement. The content is focused on share capital changes and securities movements, which aligns with announcements related to share issues or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (9434 characters) and detailed data confirm it is a substantive report, not just an announcement of a report publication or a certification. Confidence is high due to the clear focus on share capital movements and related securities information.
2022-07-06 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Pharmaron Beijing Co., Ltd. It details the issuance of capitalization shares, including the number of shares before and after the change, and confirms compliance with listing rules and legal requirements. The content focuses on share capital changes and confirmations related to share issuance, which aligns with announcements about share capital changes rather than a full financial report or earnings release. The document is about a specific share capital event and not a full report or management discussion. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a confident classification.
2022-07-05 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-06-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-06-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-06-14 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Pharmaron Beijing Co., Ltd. It references specific listing rules from the Stock Exchange of Hong Kong (SEHK) and details a bonus issue of shares, including dates, share counts, and confirmations by the board of directors. The content focuses on reporting changes in share capital rather than announcing a new report or providing financial results. It is a regulatory disclosure about share capital changes, fitting the category of Share Issue/Capital Change (SHA). The document length (9100 characters) and detailed content confirm it is not a brief announcement or a certification but a substantive disclosure of capital changes.
2022-06-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.